Literature DB >> 12760609

Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.

Rahn Kennedy Bailey1.   

Abstract

There are now five new-generation atypical psychiatric medications currently available. As these new treatments have become more common, they have grown to account for a significant percentage of all psychiatric medications prescribed. This is because of their efficacy in the treatment of several psychiatric disorders, ease of administration, and absence of the well-known extrapyramidal adverse effects long-attributed to the standard dopamine blocking anti-psychotic medications. As these medications have become treatments of choice, we have discovered additional information about their respective side effects. Issues such as bone marrow suppression, endocrine abnormalities, and most recently cardiac arrhythmia have produced concern. This paper will address all in an attempt to inform the primary care physician of the most prominent and clinically relevant adverse effects of these agents. A particular focus will address the increasing concern that these new medications can produce hyperglycemia and diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12760609      PMCID: PMC2594447     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  40 in total

1.  Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.

Authors:  I R Katz; D V Jeste; J E Mintzer; C Clyde; J Napolitano; M Brecher
Journal:  J Clin Psychiatry       Date:  1999-02       Impact factor: 4.384

2.  The distribution of body mass index among individuals with and without schizophrenia.

Authors:  D B Allison; K R Fontaine; M Heo; J L Mentore; J C Cappelleri; L P Chandler; P J Weiden; L J Cheskin
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

3.  Effect of amantadine on weight gain during olanzapine treatment.

Authors:  M Floris; J Lejeune; W Deberdt
Journal:  Eur Neuropsychopharmacol       Date:  2001-04       Impact factor: 4.600

4.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

5.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

6.  Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.

Authors:  K Atkin; F Kendall; D Gould; H Freeman; J Liberman; D O'Sullivan
Journal:  Br J Psychiatry       Date:  1996-10       Impact factor: 9.319

7.  Long-term high-dose neuroleptic treatment: who gets it and why?

Authors:  M I Krakowski; M Kunz; P Czobor; J Volavka
Journal:  Hosp Community Psychiatry       Date:  1993-07

8.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

9.  Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.

Authors:  M Tohen; T M Sanger; S L McElroy; G D Tollefson; K N Chengappa; D G Daniel; F Petty; F Centorrino; R Wang; S L Grundy; M G Greaney; T G Jacobs; S R David; V Toma
Journal:  Am J Psychiatry       Date:  1999-05       Impact factor: 18.112

10.  Olanzapine treatment for patients with schizophrenia and substance abuse.

Authors:  K H Littrell; R G Petty; N M Hilligoss; C D Peabody; C G Johnson
Journal:  J Subst Abuse Treat       Date:  2001-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.